US Innovator Expanding into Regulated & Emerging Markets

A VC-backed US company with a breakthrough Class II device had saturated its initial US niche and needed international growth to support its next funding round. Leadership was enthusiastic about “going global,” but had no in-house expertise in EU MDR, MHRA guidance, or reimbursement approaches in emerging markets.

Attempts to explore multiple countries simultaneously led to scattered conversations, inconsistent distributor quality, and growing concern from the board about regulatory risk and capital efficiency. The company faced the classic problem: broad ambition, limited bandwidth, and no global operating system.

Distributor Principles implemented the full 13-point Blueprint, prioritizing markets by reimbursement potential, regulatory complexity, and commercial fit. We executed distributor mapping and qualification in selected European and high-growth emerging markets, built clinical advocacy networks, and executed localization and registration workstreams in parallel. Contracts were structured with clear KPIs, compliance clauses, and exit mechanisms.

Within the first global cycle, the client realized outcomes such as entry into 3 priority countries, 4% of revenue coming from outside the US, and a 12% uplift in valuation narrative due to demonstrable international traction and a credible global scaling plan.